Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 295 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab June 11, 2021 Abnormal Results from Prenatal Blood Test Could Point to Cancer in... February 21, 2025 Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... April 17, 2019 Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia June 17, 2019 Load more HOT NEWS ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors? ESMO awards its first fellowship to support digital and computational pathology Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991
